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OBJECTIVES: To describe the referrals and their flow within and outside  
the referral networks, and examine the effects of the audit on the adherence  
to referral guidelines and quality of services. METHODS: First, series of meetings 
were held with study teams (5 referral networks, district and regional 
management officers) to provide a framework for the referral cycle.  
The framework then provided the basis for the implementation of 2 referral 
audit cycles of 3 months each by each referral network. The audit cycle involved 
data collection, analysis, action plan formulation, action plan implementation, 
and reassessing the situation with another cycle. A total of 12 health centers  
and 4 hospitals participated in the study. The first 4 referral networks had a 
midwife and the head midwife from the health centres district hospital 
respectively as member. The lead midwifes from the district and regional 
hospitals constituted the fifth network. RESULTS: Over 90% of the 446 referrals 
were mothers with maternal related complications. Cycle 2 findings shows 
improvement in quality of care provided for patients. For instance, an increase 
in; partograph use from 40% to 50%, feedback to home facility from 37% to  
58%, health worker accompanying referred patient from 64% to 80%, health 
workers calling ahead of referrals from 38% to 65%, and absence of key staff 
decreased about 20% to 2%. Poor adherence to referral procedures, lack of 
networking among providers, absence of key staff, Socio-cultural beliefs, poor 
transportation were the main barriers to quality of care. CONCLUSIONS: 
Establishment of formal and informal networks among providers, community 
level engagement, and availability of referral protocol and adherence facilitate 
good quality of care.  
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OBJECTIVES: To examine the effects of U.S. federal parity legislation on 
substance use disorder treatment in the first year after passage. METHODS: We 
used insurance claims data from Aetna Inc. health plans in ten states with state-
level parity laws for substance use disorder treatment. We used a difference-in-
differences study design to compare changes in outcomes among self-insured 
health plan enrollees subject to federal parity in the years before and after 
implementation of federal parity (2009-2010) with changes in outcomes among a 
comparison group of fully insured health plan enrollees previously covered by 
state substance use disorder parity laws (N=298,339). Outcomes included: shares 
of enrollees using any substance use disorder treatment; annual total spending 
on substance use disorder treatment; out-of-pocket spending on substance use 
disorder treatment and three substance use disorder performance measures: 
identification, treatment initiation and treatment engagement. RESULTS: In the 
first year of implementation, federal parity did not lead to changes in the 
proportion of enrollees using substance use disorder treatment. Total spending 
on substance use disorder treatment per enrollee increased more for self-insured 
enrollees subject to federal parity than for fully-insured enrollees ($16.11 vs. 
$6.12, difference $9.99, 95% CI: $2.54 to $18.21). Federal parity was not associated 
with any statistically significant changes in identification, treatment initiation or 
treatment engagement. CONCLUSIONS: Inclusion of substance use disorder 
services in the federal parity law did not result in substantial increases in health 
plan spending. It will be critical to evaluate the effects of federal parity in more 
recent data, after regulations affecting the management of care (e.g., utilization 
review, network access) took effect.  
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OBJECTIVES: Abdominal aortic aneurysm (AAA) is typically asymptomatic,  
but over time may lead to a rupture of the aorta, with a high fatality rate. The 
Screening AAA Very Efficiently (SAAAVE) Act of 2007 adds a new preventative 
service as part of the Welcome to Medicare visit (WTM), a free one-time AAA 
screening for men with smoking history, and men and women with a family 
history of AAA. This study aimed to estimate utilization of the new benefit  
and its impact on AAA diagnostics and treatment. METHODS: We analyzed 
Medicare claims data (2005-2009) to estimate Welcome to Medicare examination 
utilization (CPT codes G0344 and G0402) among new enrollees, and use of  
the new AAA screening benefit (CPT code G0389). We also examined utilization 
of AAA-related diagnostics and treatment from 2005 to 2009, i.e., two years  
prior to and following the 2007 adoption of the new benefit. RESULTS: Medicare 
data revealed very low uptake of AAA screening among newly enrolled Medicare 
beneficiaries, with rates of less than 1% each year, and under 1% among  
those eligible for the screening benefit. The number of newly enrolled 
beneficiaries newly diagnosed with AAA ranged from 6,660 to 9,260 per year, 
increasing over time. AAA-related use of abdominal ultrasound has decreased 
from 13 per 100 AAA patients in 2005 to 10 per 100 AAA patients in 2009.  
Overall AAA repair procedure rates have remained constant at 7 per 100  
AAA patients, with endovascular repair use increasing and open repair use 
decreasing. CONCLUSIONS: Medicare data showed that the Welcome to 
Medicare (WTM) visit for new enrollees and the AAA screening  
benefit established by the 2007 SAAAVE Act have been underutilized, and have 
not affected diagnostic and repair procedure rates for AAA. The need for 
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OBJECTIVES: Proton pump inhibitors (PPIs) are commonly used in children for 
treating gastroesophageal reflux disease and erosive esophagitis symptoms. 
However, the safety profile for long-term use of PPIs in children is still largely 
unclear. The objective of this study was to identify the adverse events (AEs) 
associated with pediatric PPI use and stratify them by individual PPI, age of 
patient (child versus infant), and whether the PPI was a primary suspect drug or 
used with other medications. PPI use has been related to respiratory infections 
as well as activity-related bone fractures. Children with asthma are much more 
likely to be treated with a PPI than nonasthmatic children. METHODS: A 
retrospective, descriptive analysis was conducted. Reports of AEs related to PPIs 
from 1997 through 2011 for children (aged 1-17 years) and infants (<1 year old) 
were retrieved from the FDA Adverse Event Reporting System. RESULTS: A total 
of 112,060 reports were retrieved for children. Of these, 53.8% were for 
omeprazole, 24.7% for lansoprazole, 9.9% for esomeprazole, 10.1% for 
pantoprazole, and 1.5% for rabeprazole and dexlansoprazole combined. There 
were 14,122 deaths, 9,221 associated with omeprazole. There were 46,046 initial 
or prolonged hospitalizations. There were 6093 reports of disability. The majority 
(92,954) of the reports involved concomitant use of a PPI; the PPI was the primary 
or secondary suspect drug in the remainder of the reports. There were 3,794 
reports retrieved for infants, of which 38.9% were associated with omeprazole 
and 39.8% with lansoprazole. There were 500 reports of infant deaths, with 236 
associated with omeprazole. There were 1,524 events involving hospitalization. 
Concomitant use of PPIs accounted for 3198 (84.3%) of the reports. 
CONCLUSIONS: Pediatric PPI-related AEs involved death, hospitalization, 
disability, and life-threatening outcomes. Further investigation is warranted. 
Currently, the FDA recommends that health care providers deliver the shortest, 
lowest-dose PPI regimen as possible.  
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OBJECTIVES: To investigate the characteristics of Chronic Hepatitis C (CHC) 
patients, their co-morbid conditions, treatments and associated costs using large 
health care payer databases. METHODS: This retrospective study used data from 
Truven Health Analytics MarketScan databases from January 1, 2006-March 31, 
2012. Adult patients with ≥2 diagnosis claims of chronic HCV (CHC) were 
selected. They had at least six months of continuous health plan and drug plan 
enrollment pre/post index date. CHC patients were grouped by disease severity 
as non-cirrhotic disease (NCD), compensated cirrhosis (CC), or end-stage liver 
disease (ESLD). Co-morbidities, treatment rates, health care utilization, and cost 
were assessed by disease severity. RESULTS: 57,084 CHC patients met inclusion 
criteria, of whom 43,561 (76.3%) were NCD, 6,830 (12.0%) were CC, and 6,693 
(11.7%) were ESLD. Mean age was 50.6 yrs [standard deviation (SD) =10.1]. 58.1% 
of patients were male and 73.8% had commercial insurance. Common co-
morbidities included type II diabetes (DM) (13.3%), substance abuse (14.5%), and 
depression (11.7%). Diagnosis of DM and substance abuse increased with disease 
severity (DM diagnosed in 14%/20%/27% and substance abuse in 20%/22%/26% of 
NCD/CC/ESLD CHC patients, respectively). Detection of all three co-morbidities 
increased following HCV diagnosis. Depression increased from 12% to 16% 
following HCV diagnosis. Anemia was highly prevalent following diagnosis 
(12.3%), especially in the ESLD cohort (28.3%). In the six months following HCV 
diagnosis, utilization of inpatient, hospital outpatient, emergency room, 
physician office, and pharmacy services increased significantly. During the study 
period, 10.9% of the population received treatment for HCV, 83.1% with dual 
therapy compared to 13.2% with telaprevir and 3.4% with boceprevir-based triple 
therapy. The modest use of the protease inhibitors likely reflects their coming to 
market in 2011. CONCLUSIONS: A small percentage of CHC patients receive 
treatment. DM, substance abuse, and depression are common among patients 
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OBJECTIVES: Baseline viral load (BVL) is a known predictor of time to treatment 
response (achievement of undetectable viral load, UVL) in CHB studies. No 
